Loading…
Moderna, Inc. is projected to rise to $53.68 by 2027, a +13% move from its current price of $47.61. MRNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $46.27 | $47.63 | $49.04 | +0.05% |
| May 30 | $45.74 | $47.65 | $49.65 | +0.09% |
| May 31 | $45.34 | $47.68 | $50.14 | +0.14% |
| Jun 1 | $45.01 | $47.70 | $50.55 | +0.19% |
| Jun 2 | $44.72 | $47.72 | $50.92 | +0.23% |
| Jun 3 | $44.47 | $47.74 | $51.26 | +0.28% |
| Jun 4 | $44.23 | $47.77 | $51.58 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $44.23 | $47.77 | $51.58 | +0.33% |
| Week 2 | $42.99 | $47.92 | $53.42 | +0.66% |
| Week 3 | $42.09 | $48.08 | $54.92 | +0.98% |
| Week 4 | $41.37 | $48.24 | $56.25 | +1.31% |
| Week 5 | $40.76 | $48.39 | $57.46 | +1.65% |
| Week 6 | $40.22 | $48.55 | $58.60 | +1.98% |
| Week 7 | $39.75 | $48.71 | $59.69 | +2.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Moderna, Inc. is a biotechnology company that develops messenger RNA medicines for use in the United States, Europe, and internationally. Its portfolio includes respiratory vaccines such as spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination vaccines, and pandemic influenza vaccines.
The company also has latent vaccines targeting cytomegalovirus, Epstein-Barr virus, and HIV; enteric vaccines for norovirus; public health vaccines including Zika, Nipah, and Mpox; and bacterial vaccines such as Lyme. In addition to vaccines, Moderna provides oncology therapeutics and rare-disease products. It maintains strategic alliances with Merck & Co., Vertex Pharmaceuticals (and Europe), immatics N.V., DARPA, BARDA, the Institute for Life Changing Medicines, The Bill & Melinda Gates Foundation, and OpenAI.
Moderna, Inc. was formerly Moderna Therapeutics, Inc. and was renamed in August 2018. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc. (MRNA) is currently priced at $46.88 and has a market capitalization of $18.6B, ranking 618 by market cap. The current price sits within a broader market position that reflects a mid-cap biotechnology footprint.
The 30-day forecast aligns with a neutral stance, illustrating a path with modest upside and downside potential around the current price. The multi-year outlook shows meaningful upside, with bullish thrust developing into the 2030s and beyond.
A major floor 17.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key MRNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $47.38 | Buy | $47.46 | Buy |
| MA 10 | $48.02 | Sell | $47.98 | Sell |
| MA 20 | $48.45 | Sell | $48.75 | Sell |
| MA 50 | $50.40 | Sell | $49.12 | Sell |
| MA 100 | $47.97 | Sell | $46.35 | Buy |
| MA 200 | $37.26 | Buy | $42.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.54 | Neutral |
| Stoch RSI (14) | 29.49 | Neutral |
| CCI (20) | -28.60 | Neutral |
| Williams %R (14) | -78.10 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -12.40 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 21.90 | Neutral |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -2.66 | Sell |
| Ultimate (7,14,28) | 42.53 | Neutral |
| Momentum (10) | -5.66 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 46.90 | Buy |
| ADX (14) | 12.86 | Neutral |
| ATR (14) | 1.28 | Info |
Technically, the near term has a neutral tilt. The RSI(14) is 40, suggesting room for potential upside without being overbought. The 50-day simple moving average sits at $50.62, while the 200-day moving average is $37.05, indicating longer-term support beneath recent levels.
Support is identified at $45.37 and resistance at $55.60. The 30-day trading range spans from $38.29 to $57.40, highlighting recent volatility within a defined interval.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.86 | $47.61 | $65.53 | 0% | Neutral | |
| $42.31 | $53.68 | $72.30 | +13% | Neutral | |
| $44.54 | $58.17 | $81.35 | +22% | Bullish | |
| $43.72 | $58.51 | $84.29 | +23% | Bullish | |
| $50.04 | $68.43 | $101.09 | +44% | Bullish | |
| $58.12 | $81.07 | $122.42 | +70% | Bullish | |
| $60.50 | $85.97 | $132.40 | +81% | Bullish | |
| $67.27 | $97.27 | $152.50 | +104% | Bullish | |
| $64.73 | $95.16 | $151.67 | +100% | Bullish | |
| $61.62 | $92.04 | $148.94 | +93% | Bullish | |
| $89.53 | $143.78 | $248.07 | +202% | Bullish | |
| $154.06 | $280.63 | $531.46 | +489% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $30.86 | $47.61 | $56.06 | +0.00% |
| June 2026 | $41.87 | $49.25 | $59.34 | +3.43% |
| July 2026 | $41.87 | $49.68 | $60.72 | +0.88% |
| August 2026 | $41.27 | $49.31 | $60.94 | -0.74% |
| September 2026 | $42.28 | $50.81 | $63.35 | +3.04% |
| October 2026 | $43.43 | $52.48 | $65.96 | +3.29% |
| November 2026 | $42.71 | $51.85 | $65.63 | -1.20% |
| December 2026 | $42.17 | $51.43 | $65.53 | -0.82% |
Click any year to see its month-by-month MRNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MRNA to range from $30.86 to $65.53 through 2026. The $47.61 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MRNA price prediction for 2027 points to an average of $53.68 (low $42.31, high $72.30) — a potential gain of +13% on today's $47.61. Price action looks broadly range-bound.
In 2028, MRNA is projected to trade between $44.54 and $81.35, averaging $58.17 — a potential gain of +22% from today's $47.61. That is up +8% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Moderna, Inc.'s 2029 outlook centres on $58.51, within a $43.72 to $84.29 range. That is up +1% on the projected 2028 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2030, MRNA could reach as high as $101.09, with a base case around $68.43 and support toward $50.04 — roughly +44% from $47.61. Buyers look set to stay in control over this stretch.
Expect MRNA to range from $58.12 to $122.42 through 2031. The $81.07 average target implies a +70% move from current prices. That is up +18% on the projected 2030 average. Momentum favours further upside here.
The MRNA price prediction for 2032 points to an average of $85.97 (low $60.50, high $132.40) — a potential gain of +81% on today's $47.61. Buyers look set to stay in control over this stretch.
In 2033, MRNA is projected to trade between $67.27 and $152.50, averaging $97.27 — a potential gain of +104% from today's $47.61. That is up +13% on the projected 2032 average. Momentum favours further upside here.
Moderna, Inc.'s 2034 outlook centres on $95.16, within a $64.73 to $151.67 range. That is -2% versus the projected 2033 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MRNA could reach as high as $148.94, with a base case around $92.04 and support toward $61.62 — roughly +93% from $47.61. Momentum favours further upside here.
Expect MRNA to range from $89.53 to $248.07 through 2040. The $143.78 average target implies a +202% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MRNA price prediction for 2050 points to an average of $280.63 (low $154.06, high $531.46) — a potential gain of +489% on today's $47.61. Momentum favours further upside here.
Investing $1,000 in MRNA today (≈ 21.003991 MRNA) could be worth
$5,894.38
+$4,894.38 (+489%) by 2050 · US Dollar
Based on the average projected MRNA price of $280.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRNAwould be worth at today's price.
$1,000 invested in MRNA on May 27, 2025 (≈ 37.369207 MRNA) would be worth
$1,779.15
+$779.15 (+77.9%) today · 1.78× · US Dollar
Based on a MRNA entry price of $26.76 vs. today's $47.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $48.12 | $989.4 | -1.1% |
| 1 month ago | $48.7 | $977.62 | -2.2% |
| 3 months ago | $51.71 | $920.71 | -7.9% |
| 6 months ago | $25.98 | $1,832.56 | +83.3% |
| 1 year ago | $26.76 | $1,779.15 | +77.9% |
| All time (5.0y) ago | $184.66 | $257.83 | -74.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRNA forecast.
Our base-case forecast reaches $95.00 around 2033.
Implied market cap at $95.00: $37.69B
The year-by-year forecast shows a developing bullish trajectory after 2026. In 2026, the average price is forecast at $46.88 with a max of $65.10 and a min of $30.86, yielding a 0% ROI and a neutral sentiment. By 2027, the average rises to $52.60 with a 12.2% ROI and a neutral sentiment.
The forecast strengthens into 2028 with an average of $56.49 and a 20.5% ROI, followed by 2029 with an average of $56.87 and a 21.3% ROI, both still labeled bullish. The 2030 forecast shows an average of $66.20 and a 41.2% ROI with a bullish sentiment, continuing to 2031 (avg $78.37, ROI 67.2%), 2032 (avg $83.72, ROI 78.6%), and 2033 (avg $94.38, ROI 101.3%). The long horizon remains bullish through 2034–2035, with averages approaching $91.02 and $88.12 and ROI in the 90s.
In 2040, the average forecast climbs to $136.93 with a 192.1% ROI, and by 2050 the average is $268.47 with a 472.7% ROI, with the max forecast at $519.83. These figures indicate a sustained bullish outlook at the long end of the horizon. The forecasts acknowledge uncertainty and are estimates, not guarantees.
Driving factors are not specified, but the data show a clear upward trajectory in average prices and expanding upside potential over time.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $66.20 with a 41.2% ROI. The 2030 range is a min of $47.86 and a max of $99.03.
Forecasts indicate bullish sentiment from 2027 onward, with the average price rising to $66.20 by 2030 and up to $268.47 by 2050, translating to increasing ROIs (41.2% in 2030 and 472.7% by 2050). These are estimates and not guarantees.
The 2030 maximum is $99.03, which is below $100. However, the 2040 maximum is $240.74 and the 2050 maximum is $519.83, indicating potential for prices above $100 in later years.
The current price is $46.88 and the market capitalization is $18.6B.
The 2050 forecast shows an average price of $268.47 with a 472.7% ROI and a maximum of $519.83.
Moderna, Inc. Community Discussion
0Share your Moderna, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.